Ceyhan Balcı ŞENGÜL, Cem ŞENGÜL, GÜLŞEN ÜNLÜ, Ahmet BÜBER, Kamuran KARAKÜLAH, Hasan HERKEN

Effect of adult attention deficit hyperactivity symptoms on smoking cessation

Objective: Nicotine addiction is the most prevalent addiction type all over the world and attention deficit hyperactivity disorder (ADHD) is an important factor associated with nicotine addiction. Primary aim of this study was to evaluate the effect of ADHD symptoms on smoking cessation. Methods: Smokers who had admitted to the smoking cessation center were evaluated with using Wender Utah and Fagerstorm Scales at the beginning of study and for the success of smoking cessation at the end of 6 months. Results: Of the 353 smokers enrolled to the study, 99 individuals had a score of 36 or higher on Wender Utah scale (ADHD symptoms group). Of these 99 patients with ADHD symptoms, 11 (11.1%) and of the 254 non-ADHD symptoms group, 68 (26.8%) had quitted smoking after a period of six months. Logistic regression analysis revealed that having ADHD symptoms predicted failure of smoking cessation (adjusted odds ratios 2.12, 95% confidence interval 1.02-4.40) after controlling for sociodemographic and smoking-related variables. Conclusions: ADHD symptoms may be an important factor affecting smoking cessation. Examining these symptoms in problematic nicotine addicts might help treatment outcome.

Erişkin dikkat eksikliği hiperaktivite bozukluğu belirtilerinin sigara bırakma üzerine etkisi

Amaç: Nikotin bağımlılığı dünyada en sık görülen bağımlılık tiplerinden biridir ve dikkat eksikliği hiperaktivite bozukluğu (DEHB) nikotin bağımlılığı ile ilişkili olan önemli bir etkendir. Bu çalışmanın temel amacı, DEHB belirtilerinin sigara bırakma üzerine olan etkisini değerlendirmektir. Yöntem: Sigara bırakma merkezine başvuran sigara kullanıcıları, çalışmanın başında ve altı ay sonunda sigara bırakma başarısı için Wender Utah ve Fagerstorm Ölçekleri kullanılarak değerlendirildi. Sonuçlar: Çalışmaya alınan 353 sigara kullanıcısından 99'unun Wender Utah Ölçeğinde 36 veya daha yüksek bir puanı vardı (DEHB belirtileri grubu). DEHB belirtileri olan 99 hastadan 11'i (%11.1) ve DEHB belirtileri olmayan 254 kişilik grubun 68'i (%26.8) altı aylık süre sonrasında sigarayı bırakmıştır. Lojistik regresyon analizi, sosyodemografik ve sigarayla ilişkili değişkenler kontrol edildikten sonra DEHB belirtileri olanların sigarayı bırakma (düzeltilmiş tahmini göreli risk 2.12, %95 GA 1.02-4.40) konusunda başarısız olabileceğini göstermiştir. Tartışma: DEHB belirtileri sigara bırakmayı etkileyen önemli bir etken olabilir. Nikotin bağımlılığı olanlarda bu belirtilerin incelenmesi tedavi sonucuna yardım edebilir.

PDF

___

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (Text Revised). Washington, DC: American Psychiatric Association, 2000.

Salín-Pascual RJ, Alcocer-Castillejos NV, AlejoGalarza G. Nicotine dependence and psychiatric disorders. Rev Invest Clin 2003; 55(6):677-693.

McClernonFJ, Kollins SH. ADHD and smoking: from genes to brain to behavior. Ann N Y Acad Sci 2008; 1141:131-147.

Wolraich ML, Wibbelsman CJ, Brown TE, Evans SW, Gotlieb EM, Knight JR, et al. Attentiondeficit/hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implications. Pediatrics 2005; 115(6):1734-1746.

Wilens T. Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues. Psychiatr Clin North Am 2004; 27:283-301.

Pomerleau OF, Downey KK, Stelson FW, Pomerleau CS. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse 1995; 7:373-378.

Veselska Z, MadarasovaGeckova A, Reijneveld SA, van Dijk JP. Self-efficacy, affectivity and smoking behavior in adolescence. Eur Addict Res 2011; 17(4):172-177.

Humfleet GL, Prochaska JJ, Mengis M, Cullen J, Muñoz R, Reus V, et al. Preliminary evidence of the association between the history of childhood attention-deficit/hyperactivity disorder and smoking treatment failure. Nicotine Tob Res 2005; 7(3):453-460.

McCann BS, Schele L, Ward N, Roy-Byrne P. Discriminant validity of the Wender Utah Rating Scale for attention-deficit/hyperactivity disorder in adults. J Neuropsychiatry Clin Neurosci 2000; 12:240-245.

Fagerstrom K. New perspectives in the treatment of tobacco dependence. Monaldi Arch Chest Dis 2003; 60:179-183.

Milberger S, Biederman J, Faraone SV, Chen L, Jones J. ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry 1997; 36:37- 44.

Molina BS, Pelham WE. Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD. J Abnorm Psychol 2003; 112(3):497-507.

Rohde P, Kahler CW, Lewinsohn PM, Brown RA. Psychiatric disorders, familial factors, and cigarette smoking: II. Associations with progression to daily smoking. Nicotine Tob Res 2004; 6:119-132.

Kollins SH, McClernon FJ, Fuemmeler BF. Association between smoking and attention-deficit/ hyperactivity disorder symptoms in a populationbased sample of young adults. Arch Gen Psychiatry 2005; 62:1142-1147.

Fuemmeler BF, Kollins SH, McClernon FJ. Attention deficit hyperactivity disorder symptoms predict nicotine dependence and progression to regular smoking from adolescence to young adulthood. J Pediatr Psychol 2007; 32:1203-1213.

Centers for Disease Control and Prevention. Quitting smoking among adults - United States, 2001-2010. MMWR Morb Mortal Wkly Rep 2011; 60(44):1513-1519.

Japuntich SJ, Leventhal AM, Piper ME, Bolt DM, Roberts LJ, Fiore MC, et al. Smoker characteristics and smoking-cessation milestones. Am J Prev Med 2011; 40(3):286-294.

Lee CW, Kahende J. Factors associated with successful smoking cessation in the United States, 2000. Am J Public Health 2007; 97(8):1503-1509.

Nonnemaker J, Hersey J, Homsi G, Busey A, Hyland A, Juster H, et al. Self-reported exposure to policy and environmental influences on smoking cessation and relapse: a 2-year longitudinal population-based study. Int J Environ Res Public Health 2011; 8(9):3591-3608.

Osler M, Prescott E. Psychosocial, behavioral, and health determinants of successful smoking cessation: a longitudinal study of Danish adults. Tob Control 1998; 7(3):262-267.

Lambert NM, Hartsough CS. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil 1998; 31(6):533-544.

McClernon FJ, Kollins SH, Lutz AM, Fitzgerald DP, Murray DW, Redman C, et al. Effects of smoking abstinence on adult smokers with and without attention deficit hyperactivity disorder: results of a preliminary study. Psychopharmacology 2008; 97:95-105.

Covey LS, Manubay J, Jiang H, Nortick M, Palumbo D. Smoking cessation and inattention or hyperactivity/impulsivity: A post hoc analysis. Nicotine & Tobacco Research 2008; 10:1717-1725.

Daughton D, Susman J, Sitorius M, Belenky S, Millatmal T, Nowak R, et al. Transdermal nicotine therapy and primary care. Importance of counseling, demographic, and participant selection factors on 1-year quit rates. The Nebraska Primary Practice Smoking Cessation Trial Group. Arch Fam Med 1998; 7(5):425-430.

Hagimoto A, Nakamura M, Morita T, Masui S, Oshima A. Smoking cessation patterns and predicttors of quitting smoking among the Japanese general population: a 1-year follow-up study. Addiction 2010; 105(1):164-173.

Su TT, Sallehuddin BA, Murniati HH, Swinder J, Al Sadat N, Saimy I. Factors associated with success or failure of quit attempts: a clinical approach for lung cancer prevention. Asian Pac J Cancer Prev 2012; 13(1):175-179.

Rukstalis M, Jepson C, Patterson F, Lerman C. Increases in hyperactive-impulsive symptoms predict relapse among smokers in nicotine replacement therapy. J Subst Abuse Treat 2005; 28(4):297-304.

Hurt RD, Ebbert JO, Croghan IT, Schroeder DR, Sood A, Hays JT. Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: a pilot randomized placebo-controlled trial J Negat Results Biomed 2011; 28(10):1.

Vansickel AR, Stoops WW, Glaser PE, Rush CR. A pharmacological analysis of stimulant-induced increases in smoking. Psychopharmacology 2007; 193(3):305-313.

Nunes EV, Covey LS, Brigham G, Hu MC, Levin FR, Somoza EC, et al. Treating nicotine dependence by targeting attention-deficit/hyperactivity disorder (adhd) with OROS methylphenidate: The role of baseline ADHD severity and treatment response. J Clin Psychiatry 2013; 74(10):983-990.

Kollins SH, English JS, Itchon-Ramos N, Chrisman AK, Dew R, O'Brien B, et al. A pilot study of lis-dexamfetaminedimesylate (LDX/SPD489) to facilitate smoking cessation in nicotine-dependent adults with ADHD. J Atten Disord 2014; 18(2):158- 168.

Huizink AC, van Lier PA, Crijnen AA. Attention deficit hyperactivity disorder symptoms mediate early-onset smoking. Eur Addict Res 2009; 15(1):1-9.

Wender PH, Ward MF, Reimherr FW, Marchant. Adhd in adults. J Am Acad Child Adolesc Psychiatry 2000; 39(5):543.

Fond G, Guillaume S, Jaussent I, Beziat S, Macgregor A, Bernard P, et al. Prevalence and smoking behavior characteristics of nonselected smokers with childhood and/or adult self-reported ADHD symptoms in a Smoking-Cessation Program: a cross-sectional study. J Atten Disord 2016; 95(7):e2622.

Wilens TE, Spencer TJ, Biederman J, Girard K, Doyle R, Prince J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001; 158(2):282-288.